Treatment for Heart Failure and Disparities in Minorities

Heart failure sounds as though the heart has handed in its resignation letter. Fortunately, that is not what the diagnosis means. The heart is still beating, but it cannot pump enough blood, fill normally, or meet the body’s needs without working much harder than it should.

Modern treatment for heart failure can reduce symptoms, prevent hospitalization, improve daily function, and help many patients live longer. Yet a medication cannot help someone who never receives a prescription, cannot afford the copay, lacks transportation to follow-up visits, or is not referred to a heart-failure specialist.

That is where disparities enter the story. Black, Hispanic or Latino, American Indian, Alaska Native, Asian American, Native Hawaiian, and Pacific Islander communities are not medically identical groups. However, many patients from historically marginalized populations face an uneven combination of cardiovascular risk, delayed diagnosis, insurance barriers, language differences, neighborhood disadvantage, limited specialist access, and bias within the healthcare system. The result is not merely an uncomfortable statistic. It may determine who receives lifesaving treatment early and who returns to the emergency department after the disease has progressed.

This article examines how heart failure is treated, why outcomes differ among racial and ethnic populations, and what patients, clinicians, health systems, and policymakers can do to close the gap. Current recommendations are informed by guidance from the American Heart Association, American College of Cardiology, Heart Failure Society of America, National Heart, Lung, and Blood Institute, and other major U.S. health organizations.

Understanding the Main Types of Heart Failure

Heart failure is not one single disease. It is a clinical syndrome that can develop after high blood pressure, coronary artery disease, a heart attack, cardiomyopathy, valve disease, abnormal heart rhythms, diabetes, kidney disease, congenital heart disease, certain infections, or exposure to heart-damaging medications.

Heart Failure With Reduced Ejection Fraction

Heart failure with reduced ejection fraction, commonly shortened to HFrEF, occurs when the left ventricle cannot squeeze effectively. Ejection fraction estimates the percentage of blood pushed out of the ventricle during each contraction. In HFrEF, that percentage is generally 40% or lower.

This form has the strongest collection of medications proven to reduce hospitalization and cardiovascular death. Treatment should usually begin promptly rather than adding one drug every few months while the patient and heart grow older together.

Heart Failure With Preserved Ejection Fraction

In heart failure with preserved ejection fraction, or HFpEF, the heart may squeeze normally but remain too stiff to fill properly. Patients may still experience breathlessness, swelling, exercise intolerance, and repeated hospitalization even though the ejection fraction appears “normal.” Normal-looking numbers can occasionally be excellent disguises.

HFpEF is frequently associated with hypertension, obesity, diabetes, atrial fibrillation, sleep apnea, kidney disease, and aging. Treatment focuses on relieving congestion, managing related conditions, and using therapies shown to reduce heart-failure events.

Other Heart-Failure Categories

Patients may also be diagnosed with mildly reduced ejection fraction, improved ejection fraction, right-sided heart failure, or acute decompensated heart failure. Because treatment depends on the cause, severity, symptoms, heart rhythm, kidney function, blood pressure, and ejection fraction, a complete evaluation matters. Common tests include blood work, an electrocardiogram, chest imaging, an echocardiogram, and sometimes cardiac catheterization, stress testing, magnetic resonance imaging, or genetic evaluation.

Guideline-Directed Treatment for HFrEF

For most eligible patients with reduced ejection fraction, contemporary guideline-directed medical therapy is built around four foundational medication groups. Clinicians increasingly try to start all four at low or moderate doses and then adjust them as tolerated.

1. An ARNI, ACE Inhibitor, or ARB

An angiotensin receptor-neprilysin inhibitor, or ARNI, can reduce stress on the heart and lower the risk of hospitalization and death. Sacubitril combined with valsartan is the primary medication in this category.

When an ARNI is unsuitable, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker may be used. Kidney function, potassium, blood pressure, pregnancy status, prior medication reactions, and a history of angioedema must be considered.

2. An Evidence-Based Beta Blocker

Carvedilol, sustained-release metoprolol succinate, and bisoprolol are beta blockers with evidence supporting their use in HFrEF. These medicines slow the heart, reduce harmful stress-hormone activity, and can improve heart function over time.

Beta blockers are usually started when the patient is clinically stable. Fatigue or dizziness may occur during early adjustment, but that does not automatically mean the medication has failed. It may simply mean the dose needs a slower introduction rather than a dramatic farewell ceremony.

3. A Mineralocorticoid Receptor Antagonist

Spironolactone or eplerenone may reduce hospitalization and mortality in appropriate patients. Because these drugs can raise potassium and affect kidney function, laboratory monitoring is essential. Access to timely blood testing is therefore part of treatment, not an optional administrative decoration.

4. An SGLT2 Inhibitor

Sodium-glucose cotransporter-2 inhibitors were originally developed for diabetes, but their cardiovascular benefits extend to many people with heart failure who do not have diabetes. Dapagliflozin and empagliflozin are commonly used examples. These medicines can reduce heart-failure hospitalization and cardiovascular risk across a broad range of ejection fractions.

Patients should receive guidance about hydration, genital infections, temporary medication pauses during serious illness or prolonged fasting, and the rare possibility of ketoacidosis. Clinical benefit does not cancel the need for practical education.

Additional Medications

Loop diuretics such as furosemide, bumetanide, or torsemide help the kidneys remove excess sodium and water. They can quickly improve swelling and breathlessness, although they are not substitutes for the four foundational therapies.

Selected patients may also benefit from ivabradine, digoxin, vericiguat, intravenous iron, anticoagulation for a separate indication, or medications targeting an underlying condition. Treatment should be individualized rather than assembled like an identical boxed lunch.

Hydralazine combined with isosorbide dinitrate is an evidence-based option for self-identified Black patients with persistent symptomatic HFrEF despite appropriate foundational therapy. It may also be considered when an ARNI, ACE inhibitor, or ARB cannot be used. This recommendation reflects clinical-trial evidence and should not be misinterpreted as proof that socially defined racial categories represent simple biological divisions.

Treatment for HFpEF and Mildly Reduced Ejection Fraction

SGLT2 inhibitors have become an important treatment for eligible patients with HFpEF and mildly reduced ejection fraction. Diuretics remain useful when fluid retention causes swelling or breathing difficulty. Clinicians should also manage blood pressure, atrial fibrillation, coronary disease, obesity, diabetes, sleep apnea, anemia, and kidney disease.

Mineralocorticoid receptor antagonists, ARNIs, or ARBs may be useful for selected patients, especially when the ejection fraction is closer to the lower end of the preserved range. The correct strategy depends on symptoms, laboratory results, blood pressure, and coexisting illnesses.

HFpEF treatment should not end with, “Your pumping percentage looks okay.” Patients still need an explanation, symptom management, and a plan for related conditions that may be driving the disease.

Devices, Procedures, and Advanced Heart-Failure Care

An implantable cardioverter-defibrillator may be recommended for certain patients at elevated risk of life-threatening abnormal rhythms. Cardiac resynchronization therapy can help selected patients whose ventricles do not contract together efficiently.

When coronary blockages, valve disease, or rhythm disorders contribute to heart failure, treatment may include revascularization, valve repair or replacement, ablation, or another targeted procedure.

Patients with advanced disease may require evaluation for a left ventricular assist device or heart transplant. Referral should occur before irreversible kidney, liver, nutritional, or functional decline makes the patient ineligible. Palliative care can also be introduced at any stage to improve symptom control, communication, and quality of life; it is not limited to the final days of life.

Why Heart-Failure Disparities Persist in Minority Communities

Unequal Exposure to Major Risk Factors

High blood pressure is one of the strongest preventable causes of heart failure. Recent CDC data show that hypertension is more common among non-Hispanic Black adults than among several other major racial and ethnic categories. Earlier onset, delayed control, medication costs, chronic stress, environmental exposures, and limited access to continuous primary care can allow hypertension to damage the heart for years.

Diabetes, obesity, kidney disease, tobacco exposure, and coronary artery disease also interact with neighborhood conditions. Advising someone to “eat fresh food and exercise” may be technically reasonable, but the advice becomes rather flimsy when the nearest grocery store is miles away, sidewalks are unsafe, work schedules are unpredictable, or healthy food costs more than the family can spend.

Delayed Diagnosis and Limited Specialty Care

Early heart-failure symptoms are easy to misinterpret. Fatigue may be blamed on work, aging, stress, or body weight. Breathlessness may be treated as a lung problem without a cardiac evaluation. Swelling may be dismissed until it becomes severe.

Research has found that Black and Latino patients hospitalized with heart failure may be less likely to receive care on a cardiology service. Since specialty involvement can affect diagnostic testing, medication optimization, device evaluation, and advanced-therapy referral, the location of care can shape the treatment pathway.

Medication Affordability and Treatment Complexity

A heart-failure regimen may involve several daily medicines, laboratory appointments, transportation expenses, dietary adjustments, home blood-pressure checks, and frequent follow-up. A patient choosing between rent, food, and an expensive prescription does not have an “adherence problem.” The patient has an affordability problem wearing a medical name tag.

Formulary restrictions, prior authorization, unstable insurance, pharmacy shortages, and a lack of paid leave can delay therapy. Even inexpensive generic drugs may become inaccessible when appointments, laboratory tests, parking, childcare, and transportation are included.

Language, Communication, and Trust

Patients with limited English proficiency may receive technically correct instructions that are practically unusable. Professional interpreters, translated medication lists, plain-language explanations, and teach-back methods are safer than relying on hurried relatives or a bilingual teenager who did not volunteer to become the family’s cardiology department.

Trust also matters. Historical mistreatment and current experiences of dismissal, stereotyping, or rushed communication can make patients less willing to ask questions or accept new therapies. Trust is not restored by telling communities to become more trusting. It is earned through consistency, transparency, respectful care, and accountability.

Differences in Advanced-Therapy Access

Studies continue to identify racial and ethnic differences in evaluation, use, and outcomes of ventricular assist devices and heart transplantation. The pattern is complex and can vary by sex, insurance, geography, referral stage, and treatment center. Some analyses have reported lower advanced-therapy use among Hispanic patients, while others have identified inequities affecting Black patients during evaluation or transplantation.

These findings should not be reduced to a claim that minority patients are automatically denied care everywhere. They do show that referral criteria, social-support assessments, center practices, implicit bias, and structural barriers deserve close examination.

Missing and Overly Broad Data

“Asian,” “Hispanic,” “Pacific Islander,” and “American Indian or Alaska Native” are broad labels that contain communities with different histories, languages, health risks, and access to care. Combining them into large categories can hide serious local disparities.

Better data collection must be paired with community participation. Communities should not be treated merely as sources of statistics. They should help define research questions, design interventions, and determine whether a program is useful outside a conference presentation.

Practical Ways to Make Heart-Failure Treatment More Equitable

Start Proven Therapy Before Discharge

Hospitals can initiate appropriate foundational medications before discharge instead of expecting every patient to navigate multiple outpatient appointments. Discharge plans should clearly explain which medicines improve survival, which relieve symptoms, when laboratory tests are due, and whom to contact when problems arise.

Use Multidisciplinary Teams

Pharmacists can adjust medications and identify cost-saving options. Nurses can provide symptom education and follow-up calls. Dietitians can build realistic plans around cultural foods rather than issuing a joyless sheet titled “Things You May Never Eat Again.” Social workers and community health workers can address transportation, insurance, housing, and food insecurity.

Measure Treatment by Race, Ethnicity, Language, and Geography

Health systems should examine who receives each recommended medication, specialist consultation, device, and advanced-therapy referral. Data should be stratified rather than hidden inside an impressive systemwide average.

A hospital cannot fix an inequity it refuses to measure. It also should not use race as a shortcut for biology when the true issue may be insurance, neighborhood deprivation, language access, clinician decision-making, or referral patterns. AHRQ, CMS, and NIMHD resources emphasize measuring access and quality while addressing actionable social and structural causes.

Improve Follow-Up and Remote Support

Early follow-up after hospitalization can detect worsening congestion, low blood pressure, kidney problems, medication confusion, and financial barriers. Telehealth, home monitoring, mobile clinics, and community-based services may reduce travel burdens, particularly in rural and underserved areas.

Technology should expand access rather than create a new obstacle course. Programs must account for limited broadband, device costs, digital literacy, disability access, and language preferences.

Include Minority Patients in Research

Clinical trials should recruit populations that reflect the people who will eventually use the treatment. Recruitment requires more than translating a brochure. Researchers must partner with trusted community organizations, offer accessible study locations, compensate participants fairly, and return understandable results to the community.

The Jackson Heart Study demonstrates the value of long-term research focused on cardiovascular disease in African American communities. Its work examines inherited, environmental, behavioral, and social influences rather than pretending that one factor explains every disparity.

What Patients and Families Can Ask the Care Team

Patients do not need to memorize an entire cardiology textbook, which is fortunate because most textbooks are not known for their beach-read charm. A few direct questions can make appointments more productive:

• What type of heart failure do I have, and what is my ejection fraction?
• Am I eligible for all four foundational HFrEF medication classes?
• Which medicine is intended to improve survival, and which one mainly controls symptoms?
• What side effects require a phone call, and which symptoms require emergency care?
• When should my kidney function and potassium be checked?
• Would I benefit from an ICD, cardiac resynchronization, or advanced heart-failure referral?
• Are lower-cost medications, assistance programs, transportation services, or interpreter services available?

Patients should also bring a complete medication list, including over-the-counter drugs and supplements. Nonsteroidal anti-inflammatory medicines such as ibuprofen and naproxen can worsen fluid retention or kidney function in some patients. Daily weight tracking may help detect fluid buildup before breathlessness becomes severe, although the care team should provide personalized instructions about when to call.

Composite Experiences: What Equitable Heart-Failure Care Looks Like in Real Life

The following scenarios are fictional composites created from commonly reported barriers and care patterns. They are not testimonials from identifiable patients.

When Symptoms Are Dismissed

Denise, a 52-year-old Black woman, visits urgent care twice because she is exhausted, short of breath, and unable to sleep flat. She is advised to lose weight and reduce stress. Three weeks later, swelling in her legs sends her to the emergency department, where an echocardiogram reveals severely reduced heart function.

Her first hospitalization controls the fluid, but the discharge process moves faster than an airport security line five minutes before boarding. Denise leaves with several prescriptions but does not understand which ones are essential. One requires prior authorization, and another is unavailable at her neighborhood pharmacy.

Her experience changes when a heart-failure pharmacist calls, transfers the prescriptions, arranges temporary assistance, and explains the four medication groups in plain language. A nurse schedules laboratory testing near her workplace. Denise is not suddenly “more compliant.” The system has finally made the treatment possible.

When Language Access Changes the Plan

Miguel, a Spanish-speaking warehouse employee, has preserved-ejection-fraction heart failure, diabetes, and high blood pressure. His daughter usually interprets, but she cannot attend every appointment. Without a professional interpreter, he hears fragments about salt, fluids, weight, and kidney tests but misses how the instructions fit together.

During a later visit, a trained interpreter joins the conversation. A dietitian asks what Miguel actually eats instead of handing him a generic menu. Together, they identify high-sodium packaged seasonings and canned foods that can be replaced without erasing the family’s traditional meals. The clinician changes his medication schedule so it interferes less with his workday.

The medical treatment is similar, but the delivery is different. Understanding is not a bonus feature. It is part of safe prescribing.

When Geography Becomes a Medical Risk

Thomas lives in a rural American Indian community several hours from the nearest advanced heart-failure center. Bad weather, fuel costs, and unreliable transportation make frequent appointments difficult. A missed visit is recorded in his chart, but the chart does not mention the washed-out road or the truck that would not start.

A community health representative begins coordinating his care. Routine weight, blood-pressure, and symptom checks occur locally. Telehealth connects him with a cardiologist, while in-person visits are grouped on the same day. When his condition worsens, the established relationship allows an earlier referral for advanced evaluation.

Telehealth does not repair every rural access problem, but combined with local staff and reliable follow-up, it can turn distance from an invisible barrier into a manageable clinical factor.

When Medication Lists Become a Family Project

Mrs. Lee, an older Korean American patient, receives prescriptions from a cardiologist, primary care clinician, and kidney specialist. The bottles use different instructions, and several pills look nearly identical. Her son discovers she has been taking two medications from the same class because an older bottle was never removed.

At a medication-reconciliation visit, a pharmacist creates a bilingual schedule with photographs of each pill. The team contacts every prescriber and simplifies the regimen. Her family learns which symptoms signal fluid overload and which laboratory tests are required.

This experience illustrates an important point: equitable care is not achieved by prescribing the correct drug and walking away. It requires confirming that the patient can obtain, understand, tolerate, and safely continue the treatment.

Conclusion

Heart-failure treatment has improved dramatically. Many patients now have access to medications and devices that can reduce hospitalization, improve quality of life, and extend survival. Nevertheless, scientific progress does not automatically produce equitable outcomes.

Racial and ethnic disparities develop through an interconnected chain: unequal exposure to risk factors, delayed recognition, fragmented primary care, limited specialist access, medication costs, language barriers, bias, geographic isolation, and inconsistent referral for advanced therapies. Breaking that chain requires action at every level.

Clinicians can prescribe evidence-based treatment promptly and communicate respectfully. Hospitals can measure differences in treatment and outcomes. Insurers can reduce delays and financial barriers. Researchers can include communities that have historically been overlooked. Policymakers can strengthen access to primary care, medications, nutritious food, transportation, interpreters, and specialty services.

The goal is not special treatment for minority patients. It is reliable access to the same high-quality, individualized heart-failure care every patient should already receive. The heart may be complicated, but fairness should not be.